Statins in adult patients with carotid artery disease: A protocol for a systematic review and network meta-analysis

Leonardo R[1]*, Elmiro SR[1], Angelica LDD[1], Nilson PS[1], João Lucas OC[1], Fernanda RDS[1], Poliana RAD[1], Paulo FSG[1], Hugo RZ[1,2], Anaisa Silva RB[2], Fernando CV[1], Thiago MF[1], Antonio CF[3], Paulo Magno MD[3], Antonio CPC[3,4], Sadeq Ali HAS[5], Paulo EOR[6], Rogerio de MCP[1], Gustavo BFO[7], Alvaro A[7], Mansueto N[8], Andre D[8], Rose Mary FLDS[9], Antonio JG[10], Celise D[11], Renato DL[12], Nitesh N[13], Shahab A[14], Adrian VH[15], Maria Ines DR[16], Gary Tse[16], Tong Liu[17] and Giuseppe BZ[18]

[1]Federal University of Uberlândia, Department of Clinical Research, Brazil

[2]Heart Institute (InCor), Master Institute of Education President Antonio Carlos, IMEPAC, Araguari, Brazil, Department of Clinical Research

[3]HCFMUSP- University of São Paulo Medical School, Department of Cardiology, São Paulo, Brazil

[4]Faculty of Medicine ABC, Department of Cardiology Santo André, Brazil

[5]Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Department of Cardiology, Yazd, Iran

[6]Department of Specialized and General Surgery, Fluminense Federal University, Rio de Janeiro, Brazil

[7]Dante Pazzanese Institute of Cardiology, Department of Clinical Research, Sao Paulo, Brazil

[8]Graduate Program in Medicine and Health, Department of Health and Sciences, Federal University of Bahia, Brazil

[9]Federal University of Minas Gerais, Department of Cardiology, MG, Brazil

[10]Federal University of Mato Grosso do Sul, Department of Medicine, MT, Brazil

[11]FOP Unicamp, Department of Clinical Research, SP. Brazil

[12]Division of Cardiology, Duke University Medical Center, Department of Clinical Research, Durham, NC, USA

[13]Monash Cardiovascular Research Centre and Monash Heart, Department of Cardiology, Clayton, Victoria, Australia

[14]Tehran University of Medical Sciences, Department of Medicine, Iran

[15]University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, Department of Comparative Effectiveness and Outcomes Research Health Outcomes, CT, USA

[16]Laboratory of Epidemiology, University of Extremo Sul Catarinense, Criciúma, Brazil, Department of 16Medicine and Therapeutics and Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China

[17]Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, Tianjin, China

[18]Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy

Abstract

Introduction: Atherosclerosis is now widely recognized as a multifactorial disease with outcomes that arise from complex factors such as plaque components, blood flow, and inflammation. The locations most frequently affected by carotid atherosclerosis are the proximal internal carotid artery (ie, the origin) and the common carotid artery bifurcation. Therefore, the objective of the current study is to conduct a systematic review with network meta-analysis to compare the effects of statins classes on carotid disease (CD) patients.

Methods and analysis: Randomized clinical trials (RCTs) and observational studies published in English up to 31 December 2018, and which include direct and/or indirect evidence, will be included. Studies will be retrieved by searching four electronic databases and cross-referencing. Dual selection and abstraction of data will occur. The primary outcome will all-cause mortality, new event of acute myocardial infarction, stroke (hemorrhagic and ischemic), hospitalization for acute coronary syndrome and urgent revascularization procedures and cardiovascular mortality. Secondary outcomes will be assessment of Carotid artery intima-media thickness (IMT); atherosclerotic plaque, flow-mediated dilatation (FMD); pulse wave velocity (PWV), brachial-ankle pulse wave velocity (bc), ankle-brachial pressure index (ABI), carotid atherosclerosis and carotid plaque. Network meta-analysis will be performed using multivariate random-effects meta-regression models. The surface under the cumulative ranking curve will be used to provide a hierarchy of statins that reduce cardiovascular mortality in CD patients. A revised version of the Cochrane Risk of Bias tool (RoB 2.0) will be used to assess the risk of bias in eligible RCTs. Results will be synthesized and analyzed using network meta-analysis (NMA). Overall strength of the evidence and publication bias will be evaluated.

Ethics and dissemination: Ethics approval was not required for this study because it was based on published studies. The results and findings of this study will be submitted and published in a scientific peer-reviewed journal.

PROSPERO registration number: CRD 42018083461

Strengths and limitations of this study: To the best of our knowledge, this is the first systematic review with network meta-analysis that compares the cardiovascular safety of different classes of statins drugs based on data from both randomized clinical trials (RCTs) and observational studies.

Common to most meta-analyses, significant and unexplained heterogeneity may exist. The protocol has been created according to the published PRISMA-P guidelines.

Like any aggregate data meta-analysis, the risk for ecological fallacy exists and few RCTs may report data on cardiovascular mortality.

Introduction

Rationale

Carotid artery disease (CD) is major atherosclerotic conditions that have shown an increased prevalence in the last decades and is associated with high morbidity and mortality. The carotid atherosclerotic plaque shares similar characteristics and mechanisms in the biology of the atherosclerotic process, but there are differences in the morphology and characteristics of the plaque. In fact, it has been observed that plate erosion, calcified nodules, fibrous skin thickness and macrophage accumulation may be different in the setting of coronary and carotid artery disease [1,2].

Consequently, a need exists for a meta-analysis that includes both RCTs and observational studies so that adverse outcomes can be appropriately documented. In addition, it has recently been suggested that RCTs and observational studies should not be considered in isolation. Furthermore, additional studies may have been published since the previous studies search for eligible trials (31 December 2017). Given the former, a need exists for an updated network meta-analysis that also includes observational studies.

Objective

The primary objective of this study is to conduct a systematic review with network meta-analysis of randomized trials and observational studies to compare the effects of different pharmacological classes of statins on CD and cardiovascular outcomes. The network meta-analytic approach is appropriate here because it allows for the inclusion of multiple interventions from both direct and indirect comparisons that have not been examined in a head-to-head fashion.

Methods

Overview

This study will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for meta-analyses of healthcare interventions and the current protocol report follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. This protocol is registered in International Prospective Register of Systematic Reviews (trial registration number: CRD42018083461) [3,4].

Eligibility criteria

Studies that meet the following criteria will be included: (1) randomized trials and observational studies; (2) adults ≥35 years of age with CD, either with or without a history of CV disease. (3) at least one oral statins intervention group; (4) data on CV mortality and/or major adverse cardiac events; (5) studies published in English up to 31 December 2017. The decision to include patients with CD with or without a history of CV disease was made based on our preliminary search of clinical trials that included patients with either a history of CV disease or those who are at a heightened risk for CV disease. Major adverse cardiac events will be defined as an incidence of AMI, stroke, hospitalization for acute coronary syndrome and urgent revascularization procedures.

Information sources

The following databases will be searched from their inception forward for potentially eligible studies in English language published on or before 31 December 2017: (1) PubMed, (2) Scopus, (3) Web of Science, (4) Cochrane Central Register of Controlled Clinical Trials, (5) clinical trials registry (ClinicalTrials.gov). In addition, cross-referencing from retrieved studies will be conducted.

Search strategy

Search strategies adapted from a previous research will be developed using text words and Medical Subject Headings [3]. Electronic databases will be searched for studies on the effects of statins on CV safety in adults with CD. The first author will conduct all database searches. The search strategy for all other databases will be adapted based on the requirements of each database.

Study selection

All studies extracted from electronic databases using the search strategy will be imported into EndNote V.X7.5. Duplicate studies will be removed electronically using the 'Find Duplicates' tool in EndNote. The studies will be examined again manually to find and delete any additional duplicates. The first two authors will select studies independent of each other. Complete articles will be obtained for all titles and abstracts that appear to meet the inclusion criteria or where there is any uncertainty. Reasons for exclusion will be coded as one or more of the following: (1) inappropriate population, (2) inappropriate intervention, (3) inappropriate comparison, (4) inappropriate outcome(s), (5) inappropriate study design and (6) other. After selection, the first two authors will review their selections and resolve any discrepancies by consensus. If consensus cannot be reached, the third author will be consulted. The overall agreement rate prior to correcting discrepant items will be calculated using Cohen's kappa (κ) statistics. Once discrepancies are resolved, the overall precision of searches will be calculated by dividing the number of studies included by the total number of studies screened after removing duplicates. The number needed to read will then be calculated as the inverse of the precision. A flow diagram that depicts the search process and an online supplementary file that includes a reference list of all studies excluded (including the reason(s) for exclusion) will be included in the study. The proposed structure for the flow diagram is shown in (Figure 1).

Data abstraction

Before initiating data abstraction, a codebook will be developed in Microsoft Excel 2013. The codebook will be developed by the first author with input from the third author. The major categories of variables to be coded will include: (1) study characteristics (author, journal, year, etc); (2) participant characteristics (age, sex, CV disease at baseline, etc); (3) intervention characteristics (pharmacological class of statins, dose, etc); (4) control characteristics; (5-6) outcome data for CV mortality, all-cause mortality, incidence of AMI, stroke, hospitalization for acute coronary syndrome and urgent revascularization procedures. The first two authors will abstract data from selected studies, independent of each other, using the codebook in Microsoft Excel. On completion, both authors will review the codebooks and resolve discrepancies by consensus. If consensus cannot be reached, the third author will provide a recommendation. Prior to correcting disagreements, the overall agreement rate will be calculated using Cohen's κ statistic.

Outcomes and prioritization

The primary outcome will all-cause mortality, new event of acute myocardial infarction, stroke (hemorrhagic and ischemic), hospitalization for acute coronary syndrome and urgent revascularization procedures and cardiovascular mortality. Secondary outcomes will be assessment of Carotid artery intima-media thickness (IMT); atherosclerotic plaque, flow-mediated dilatation (FMD); pulse

Figure 1. Flow diagram of study selection process

wave velocity (PWV), brachial-ankle pulse wave velocity (bc), ankle-brachial pressure index (ABI), carotid atherosclerosis and carotid plaque.

Risk of bias assessment in individual studies

Two reviewers will independently assess the risk of bias for each included study using the modified version of the Cochrane Collaboration tool. Risk of bias assessment will be performed for individual studies separately for each outcome [5,6]. A third reviewer will resolve disagreements.

The included RCTs will be assessed for sequence generation, allocation sequence concealment, blinding, selective outcome reporting and missing participant data. Sequence generation will be considered adequate if the study explicitly described an appropriate randomization procedure to generate an unpredictable sequence of allocation, including computerized randomization, use of random number tables and coin-tossing. Concealment of allocation will be considered adequate if specific methods to protect allocation were documented and implemented. Performance bias will be considered low if a study reported participant, caregiver and/or researcher blinding. Blinding of outcome assessment will be considered adequate if outcome assessors and adjudicators were blinded. Within-study selective reporting of outcomes will be examined by reviewing the a priori study protocol, if available. If the study protocol is not available, we will compare the outcomes listed in the methods section with the reported outcomes in the results section.

A description for each domain assessed will be included along with comments if necessary and a final judgement for each outcome within each study and categorized as (1) low risk of bias, where bias is not present or, if present, unlikely to affect outcomes; (2) probably low risk of bias; (3) probably high risk of bias; or (4) high risk of bias, where outcomes are likely to be significantly affected by bias.

Data synthesis

Calculation of effect sizes

All analyses will be conducted using the natural log of OR and then transformed back to ORs for presentation purposes. If OR is not reported, it will be calculated from data reported in the study. If data are not available to calculate OR, it will be requested from the study authors. Secondary outcomes will be calculated using the same procedure as for our primary outcome. If a study includes both direct and indirect comparisons, only direct comparison data will be included given that the primary focus of the current study is to compare the CV safety between different statins. The data augmentation approach will be used to make direct comparisons if the control group is placebo. In this technique, direct evidence studies that lack a control (placebo) group will have one generated from the weighted average of the arm-specific means and SD [7,8].

Pooled estimates for change in outcomes

Network maps will be drawn to depict the treatments that are directly compared against each other and the amount of evidence

available for each treatment and its comparator. Separate network maps will be presented for each outcome. Contribution plots for each outcome will be generated to determine the most dominant comparisons for each network estimate, as well as for the entire network. The weights applied will be a function of the variance of the direct treatment effect and the network structure, the product being a percent contribution of each direct comparison to each network estimate. Network and contribution plots will be produced using the *networkplot* and *netweight* commands, respectively, in Stata/IC for Mac V.14.0 (STATA; 2016) [9].

Prior to conducting network meta-analysis, pairwise meta-analysis using random-effects models will be conducted in order to examine statistical heterogeneity within each comparison. Heterogeneity will be assessed using Cochran's Q statistics and I^2, an extension of Q [10]. A Q statistic <0.10 and/or an I^2 value >50% will be considered to represent significant heterogeneity. On completion of pairwise meta-analysis, network meta-analysis will be performed using multivariate random-effects models based on the *mvmeta* command in Stata/IC for Mac V.14.0. Non-overlapping 95% CIs will be considered to represent statistically significant changes [11,12]. Separate network meta-analysis models will be used to compare CV mortality, all-cause mortality, incidence of AMI, stroke, hospitalization for acute coronary syndrome and urgent revascularization procedures.

Sub-group analyses will be conducted to examine the association between our primary outcome and oral statins. These will include year of drug approval by the US FDA, presence or absence of CV disease risk at baseline, lipids at the baseline, number of comorbidities, type of treatment (monotherapy, dual therapy or triple therapy) and the country the study was conducted in. Secondary outcomes will be handled using the same approach.

We will examine the consistency of the estimates of treatment effects from direct and indirect evidence for each outcome using the *mvmeta* command in Stata. An alpha value < 0.05 will be considered to represent statistically significant inconsistency [8]. Prediction intervals will be used to enhance the interpretation of findings and provide an estimate of expected results in a future study. Prediction intervals will be generated using the *mvmeta* and interval plot commands in Stata/IC for Mac V.14.0 [8-12]

Meta-biases

Small-study effects (publication bias, etc) will be assessed using comparison-adjusted funnel plots. Unlike traditional funnel plots in pairwise meta-analysis, funnel plots in network meta-analysis need to account for the fact that studies estimate treatment effects for different comparisons. Consequently, there is no single reference line from which symmetry can be evaluated. For the comparison-adjusted funnel plot, the horizontal axis will represent the difference between study-specific effect sizes from the comparison-specific summary effect. In the absence of small-study effects, the comparison-adjusted funnel plot

should be symmetric around the zero line. Since the treatments need to be organized in some meaningful way to examine how small studies may differ from large ones, comparisons will be defined so that all refer to an active treatment versus a control group. Comparison-adjusted funnel plots will be generated using the *netfunnel* command[9] in Stata/IC for Mac V.14.0.

Transitivity (similarity in the distribution of potential effect modifiers across the different pairwise comparisons) will be evaluated using random-effects network meta-regression while controlling for the different study designs within each comparison [13]. Potential effect modifiers will include age, gender, baseline lipids, obesity, presence of CV disease at baseline and medication status. In addition, because individuals taking medication are more likely to have severe disease or more comorbidity than those without medication, we will also include baseline condition of the patient (e.g., disease severity) in our regression models. However, since this is an aggregate data meta-analysis and if the patients included within each study are heterogeneous (e.g., different levels of disease severity within the same study), we will include as a covariate those studies that control for such factors versus those that do not. Table 1 provides a complete list of covariates that we plan to include. Transitivity analysis will be conducted using the *mvmeta* command in Stata/IC for Mac V.14.0. [8] [Table 1].

AMI, acute myocardial infarction; RCT- randomized clinical trial

Ranking analysis is a major advantage of network meta-analysis because it allows one to rank all interventions for the outcome of interest. For the current study, we will generate ranking plots for a single outcome using probabilities. However, since ranking treatments based solely on the probability of each treatment being the best does not account for the uncertainty in the relative treatment effects and the potential for assigning higher ranks in which little information is available, *rankograms* and cumulative ranking probability plots will be used to show ranking probabilities along with their uncertainty for changes in our primary and secondary outcomes. Surface under the cumulative ranking curves (SUCRA), a transformation of mean ranks, will be used to provide a hierarchy of treatments while accounting for the location and variance of all treatment effects. Larger SUCRA values are indicative of better ranks for the treatment [14,15]. Separate ranking analyses will be conducted for all primary and secondary outcomes using the *mvmeta* and SUCRA commands in Stata/IC for Mac V.14.0. [8,9].

Software used for data synthesis

All data will be analyzed using Stata/IC for Mac V.14.0.

Confidence in the cumulative evidence

Strength in the body of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation

Table 1. Covariates that will be included in the study

Characteristics	Variables
Study	Publication year, country the study was conducted in, type of study (RCT), duration of the study, follow-up duration.
Participant	Age, sex, lipids, risk of cardiovascular disease, presence or absence of cardiovascular disease, medication status, baseline condition of participants (e.g., disease severity).
Intervention	Name of the drug, pharmacological class, dose, route of administration.
Comparator	Name of the drug, pharmacological class, dose, route of administration.
Outcome	All-cause mortality, new event of AMI, stroke (hemorrhagic and ischemic), hospitalization for acute coronary syndrome and urgent revascularization procedures and cardiovascular mortality, carotid artery intima-media thickness (IMT); atherosclerotic plaque, flow-mediated dilatation (FMD); pulse wave velocity (PWV), brachial-ankle pulse wave velocity (bc), ankle-brachial pressure index (ABI), carotid atherosclerosis and carotid plaque.

(GRADE) instrument for network meta-analysis. Two main outputs are reported in a network meta-analysis: pairwise effect estimates and treatment rankings [16]. Since the two outputs are generated using different techniques, they may differ between each other. Therefore, it is important to assess the level of confidence to be placed on each output. The level of confidence will be assessed using GRADE across four domains: (1) study limitations, (2) joint consideration of indirectness and transitivity, (3) joint consideration of statistical heterogeneity and statistical inconsistency, (4) imprecision and publication bias. Based on these assessments, the overall strength of evidence will be ranked as either high, moderate, low or very low. The overall confidence will be classified as high if any one of the domains is considered high.

Risk of bias assessment

We will choose the Cochrane Collaboration's risk of bias tool to evaluate the methodological quality of RCTs. The risk of bias tool consists of six domains: sequence generation, allocation concealment, blinding, incomplete data, selective reporting and other bias. Two independent reviewers (LR and HRZ) will independently evaluate the quality of RCTs. Sequence generation will be considered as adequate if central randomization or tables of random numbers are used. Allocation concealment will be considered as adequate if central randomization or sealed envelopes are used. We will consider blinding as adequate if participants, outcome assessors and statisticians are blinded from the group assignment. The other domains will be assessed exactly as the criteria of the risk of bias tool. A summary of risk of bias of all the six domains will be provided for each trial. We choose to consider sequence generation, allocation concealment and blinding as the key essential domains to score the overall quality of a trial. Discrepancies among the two reviewers (LR and HRZ) will be solved by discussion or will be judged by a third reviewer (GBZ).

Statistical analysis

The data for statistical analysis will be extracted into an Excel file. The primary outcome is continuous data, so we will calculate the effect size of the interventions using the standardized mean difference (SMD). For trials that present mean values of each time point, we will use the primary outcome adjusted by the baseline values. If the trials present the value of the primary outcome changing from baseline, we will calculate the SMD directly. We will calculate the 95% CI for each single SMD, and the results will be pooled using the random-effect model. The proportion of responders represents dichotomous data, so we will calculate the effect size using the relative ratio (RR). The RR and the 95% CI of each intervention will be calculated and pooled using the random-effect model.

The network meta-analysis will be conducted using the 'netmeta' package in the R software (http://www.r-project.org/), to combine direct and indirect evidence of interventions for migraine prophylaxis.[6] The package is developed on the basis of the frequentist method, using the graph-theoretical method developed according to the electrical network theory. The first advantage of this method is that it can combine direct and indirect evidence in trials with more than two study arms [7]. Multiarm studies are often included in a network meta-analysis. In these studies, the treatment effects on different comparisons are correlated, which is not fully addressed by the generalised linear mixed models[8] or the Bayesian Markov Chain Monte Carlo method that is commonly used for network meta-analysis. The 'netmeta' package accounts for the correlated treatment effects by reweighting all comparisons of each multiarm study [8-10]. The second advantage of

this method is that it provides solutions for testing the consistency of the network using Cochrane's Q statistics and finding out the reasons for the consistency by a net-heat plot. So, we will use this method to address the consistency of the network. If the data are not suitable to carry out the synthesis, we will perform a descriptive review and summarize the evidence. The evidence strength will be assessed using the GRADE method generated by the Cochrane library. A funnel plot will be drawn to detect if there is any publication bias.

Dealing with missing data

There will be missing data in the trials that we included. We will first contact the authors to ask for original data by email or phone calls, if possible. If the original data are not available, we will try to calculate the data through the available coefficients; for example, we will calculate the SD from the 95% CI, p or t values. Imputations of the data will be tested in the following sensitivity analysis.

Subgroup analysis

To address the potential heterogeneity and inconsistency across trials, we will perform a subgroup analysis. This include subtypes of dyslipidemia (isolated hypercholesterolemia, isolated hypertriglyceridemia, mixed hyperlipidemia and isolated HDL-cholesterol reduction), blinding method (open trial, single blind for participants, double blind for both participants and care providers), quality of evidence (high risk, unclear of the risk and low risk) and mean age of the participants. Meta-regression models will be used to quantify the difference between subgroups and test for statistical significance.

Sensitivity analysis

Sensitivity analysis will be performed to first address whether the combined estimates of the interventions are dominated by one or several trials, especially those with a high risk of bias. Then we will exclude the trials to test the robustness of our study result. Second, we will test whether the imputation of the missing values affects the result of the meta-analysis. We will also test different coefficients that are used to impute the missing value; if both SE and 95% CI are available to calculate SD, we will test which is better.

Discussion

This network meta-analysis is expected to provide a ranking of the interventions from guideline recommendations for treatment for PAD, based on comparative effectiveness evidence. We also hope that the result would be of interest to the policymakers of health insurance; this might help them to make a better choice of the interventions that should be covered by insurance. Therefore, this evidence will help patients and clinicians to make decisions in such settings. The results will also aid to the development and optimization of new interventions.

Competing interests

The authors declare that they have no competing interests.

Authors contributions

LR, ASRB, ALDD, ACF, NPS, PMMD, HZ, RMLS, JLO, MN, AD, GBFO, GBZ, SAH, PEOR, AJG, RMCP, ACF, TMF, NN, SA, CD, PFSG, A.A, AVH, RDL and FCV conceived the study idea and devised the study methodology. LR, ASRB, ACPC and ESR participated in the design and coordination of the study. LR was primarily responsible for protocol writing and developed the search strategy. LR and FCV will

screen identified literature, conduct data extraction and analyses the review findings. All authors read the drafts, provided comments and agreed on the final version of the manuscript.

References

1. Sigala F, Oikonomou E, Antonopoulos AS, Galyfos G, Tousoulis D (2017) Coronary versus carotid artery plaques. Similarities and differences regarding biomarkers morphology and prognosis. *CurrOpinPharmacol* 39: 9-18. [Crossref]

2. Ball S, Rogers S, Kanesalingam K, Taylor R, Katsogridakis E, et al. (2018) Carotid plaque volume in patients undergoing carotid endarterectomy. *Br J Surg* 105: 262-269. [Crossref]

3. Shamseer L, Moher D, Clarke M (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ.* [Crossref]

4. Wannamethee SG, Shaper AG, Lennon L (2004) Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. *Heart* 90: 1398-1403. [Crossref]

5. Higgins JP, Altman DG, Gøtzsche PC (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. *BMJ.* [Crossref]

6. von Elm E, Altman DG, Egger M (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 335: 806-808. [Crossref]

7. White IR, Barrett JK, Jackson D (2012) Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. *Res Synth Methods* 3:111-125. [Crossref]

8. White IR (2015) Network meta-analysis *Stata J* 15: 951-985.

9. Chaimani A, Salanti G (2015) Visualizing assumptions and results in network meta-analysis: the network graphs package. *Stata J* 15: 905-950.

10. Rouse B, Chaimani A, Li T (2017) Network meta-analysis: an introduction for clinicians. *Intern Emerg Med* 12: 103-111. [Crossref]

11. Higgins JP, Thompson SG, Deeks JJ (2003) Measuring inconsistency in meta-analyses. *BMJ* 327: 557-560. [Crossref]

12. JP, Thompson SG, Spiegelhalter DJ (2009) A re-evaluation of random-effects meta-analysis. *J R Stat SocSer A Stat Soc* 172: 137-159. [Crossref]

13. Jansen JP, Naci H (2013) Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. *BMC Med* 11:159.

14. Chaimani A, Higgins JP, Mavridis D (2013) Graphical tools for network meta-analysis in STATA. *PLoS One.*

15. Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J ClinEpidemiol* 64: 163-171. [Crossref]

16. Salanti G, Del Giovane C, Chaimani A (2014) Evaluating the quality of evidence from a network meta-analysis. *PloSOne.* [Crossref]